Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SpikoGen
- Development stage
- Phase 3
- Lead developer
- Cinnagen
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Oral, Sublingual
01
Overview
**SpikoGen** is an adjuvanted recombinant protein-subunit vaccine for prevention of COVID-19. It contains a recombinant prefusion-stabilized extracellular-domain trimer of the SARS-CoV-2 spike glycoprotein, produced in insect cells, formulated with the Advax-CpG55.2 adjuvant system. Vaccination induces spike-directed neutralizing antibodies and cellular immune responses intended to prevent SARS-CoV-2 infection and severe COVID-19. The product was developed by Vaxine in collaboration with CinnaGen, underwent pivotal Phase 3 evaluation, and has received Iranian authorization for COVID-19 prevention, including use in children aged 5 years and older. ([tandfonline.com](https://www.tandfonline.com/doi/pdf/10.1080/21645515.2024.2363016))
- Brand names
- SpikoGenCovax-19Covax19Covax 19
- Other names
- COVAX-19COVAX19COVAX 19
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on SpikoGen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SpikoGen.